Home » Newsletters » BioWorld Science

BioWorld Science

June 25, 2001

View Archived Issues

MorphoSys and ImmunoGen expand HuCAL collaboration

Selective VPAC2 receptor agonists hold potential for type 2 diabetes Rx

Very long-acting human insulin analogue presented by Novo Nordisk at ADA meeting

DPP-IV inhibitor improves metabolic control in type 2 diabetes

Safety of single and multiple doses of NBI-6024 demonstrated in type 1 diabetics

AT-1015, a 5-HT2 antagonist, improves nerve blood flow and sensory/motor deficits in diabetic rats

ADA news: preclinical findings support potential of FK-614 in type 2 diabetes

Initiation of phase III trials of TSE-424 triggers milestone payment from Wyeth to Ligand

NN-2211: preclinical and clinical data discussed at ADA scientific sessions

Corixa and Kirin form alliance for therapeutic monoclonal antibodies

Yasmin now available in the U.S.

Atovaquone nanosuspensions have excellent therapeutic efficacy in toxoplasmosis

AstraZeneca's Zomig approved in Japan for migraine

FDA issues nonapprovable letter to Wyeth-Ayerst for long-bone fracture therapy

DepoMed commences phase III trial of Metformin GR for type 2 diabetes

Nortran's antiarrhythmic agent shows oral bioavailability

Kosan Biosciences awarded SBIR grant for epothilone development

UroGenesys changes name to Agensys

NAVIGATOR trial to study nateglinide/valsartan for diabetes and cardiovascular disease prevention

Results for Vasogen's immune modulation therapy to be presented in September

Prous Science launches Integrity --the world's first integrated drug discovery portal

Heterocyclic compounds useful as medicines described by SCRAS

Methods of inhibiting ApoB secretion and/or inhibiting MTP patented by Pfizer

Japan Energy identifies protease inhibitors for HCV

Japanese labs collaborate on discovery of new TPO receptor ligands

Sphingomyelinase inhibitors discovered in natural sources at Kitasato Institute

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...